Urolithin A Clinical Trials
“urolithin a clinical trials” is a decision-stage query. This guide focuses on what the current human evidence and product information can actually support.
What this query is really asking
“urolithin a clinical trials” is a decision-stage query. This guide focuses on what the current human evidence and product information can actually support.
Urolithin A is a postbiotic metabolite associated with ellagitannin and ellagic-acid metabolism. Human randomized studies have evaluated oral Urolithin A in middle-aged and older adults, including 500 mg and 1,000 mg daily regimens. Results have included changes in muscle-strength, endurance and mitochondrial-related biomarkers, but not every endpoint in every trial improved. That matters because a buyer page should separate promising human evidence from blanket promises.
Evidence in humans
Urolithin A is a postbiotic metabolite associated with ellagitannin and ellagic-acid metabolism. Human randomized studies have evaluated oral Urolithin A in middle-aged and older adults, including 500 mg and 1,000 mg daily regimens. Results have included changes in muscle-strength, endurance and mitochondrial-related biomarkers, but not every endpoint in every trial improved. That matters because a buyer page should separate promising human evidence from blanket promises.
What that means for a buyer
The current evidence is stronger than a purely theoretical mechanism, but weaker than a guarantee of broad anti-aging effects. Product selection should stay tied to the outcomes actually studied in humans.
Related buyer guides
What the expanded Urolithin A database changes
Phase 3 tracks 16 market entries across full-size products, formats, dose options and ingredient benchmarks. The median verified Urolithin A amount is 500 mg, but dose alone hides major differences in branded ingredient identity, testing, finished-product evidence and formula complexity.
Use the Value Index, Testing Report and Evidence Match Report alongside this guide.
Frequently Asked Questions
What is Urolithin A?
Urolithin A is a postbiotic metabolite associated with the gut-microbial transformation of ellagitannin- and ellagic-acid-derived compounds.
Is Urolithin A the same as pomegranate extract?
No. Pomegranate provides precursors, while Urolithin A is a downstream metabolite that only some people produce efficiently through their gut microbiome.
Does Urolithin A have human research?
Yes. Randomized human studies have evaluated Urolithin A in middle-aged and older adults, including muscle and mitochondrial-health outcomes.
What is mitophagy?
Mitophagy is the selective recycling of damaged mitochondria as part of cellular quality control.
Why is Urolithin A linked with mitochondria?
Urolithin A is researched for its ability to activate mitophagy-related pathways and influence mitochondrial-health biomarkers.
Is Urolithin A proven to reverse aging?
No. Human studies support specific muscle and mitochondrial-health findings, not a universal claim that it reverses human aging.
Can Urolithin A improve muscle function?
Some randomized studies reported improvements in specific muscle-strength or endurance measures, depending on the study and population.
Is more evidence still needed?
Yes. Outcomes vary by study, and broader claims require additional independent human research.
Can Urolithin A replace exercise?
No. Supplement research should not be interpreted as replacing exercise, nutrition or medical care.
How should I judge a product claim?
Match the claim to the actual human outcome studied, dose, population and formulation rather than relying on mechanism language alone.
Research references
What the mechanism tells us
Urolithin A is a postbiotic metabolite linked to ellagitannin and ellagic-acid metabolism and is studied for effects related to mitochondrial quality control, muscle function, and healthy aging. Commercial products now range from branded Mitopure formats to generic single-ingredient capsules and more complex multi-active formulas. Mechanistic research explains why scientists are interested in “Urolithin A Clinical Trials.” It can establish biological plausibility and generate hypotheses, but it does not by itself establish a meaningful human outcome.
What human studies add
Human randomized trials have evaluated daily Urolithin A doses including 500 mg and 1,000 mg and have reported changes in selected mitochondrial, muscle, or endurance-related measures. Not every endpoint improves in every study, so the literature supports a more careful interpretation than 'Urolithin A works for everything.' Human trials are useful because they test actual participants under a defined protocol. Sample size, baseline health, age, dose, duration, and endpoint all affect how broadly a result can be applied.
What the evidence still cannot prove
Red flags include implying that every 500 mg Urolithin A product is equivalent to Mitopure, borrowing a branded ingredient's certifications or clinical evidence for a generic product, and treating a larger dose as an automatic quality upgrade. Even positive human data should not be rewritten as proof of disease prevention, lifespan extension, or universal age reversal.
How Phase 3 changes this page
MitochondriaReport Phase 3 adds a larger source-backed Urolithin A market database and separates product value, testing transparency, evidence match, and formula complexity. That makes the commercial discussion less dependent on narrative reviews and more dependent on auditable product fields.
Transparency is a product feature
Two products can display the same headline dose and still differ sharply in how easy they are to verify. Clear serving information, testing disclosure, certifications, COA access, ingredient identity, and current price reduce uncertainty. They do not prove effectiveness, but they make the finished product easier to audit.
How to interpret the Value Index
The Urolithin A Value Index only applies when a current price and active dose are both verified well enough to normalize cost per 500 mg. A lower cost per 500 mg can be attractive, but it should never be confused with stronger evidence, better testing, or better clinical outcomes.
How to interpret Evidence Match
Evidence Match asks how closely the commercial product maps to the evidence used to discuss it. Timeline's Mitopure formats have a direct relationship to the branded ingredient's human clinical program. Generic products can still map to ingredient-level research, but they should not automatically inherit Mitopure-specific product evidence.
Why formula complexity matters
A single-ingredient product is easier to evaluate than a formula containing Urolithin A plus several other actives. Complexity can be useful for convenience, but it increases the number of assumptions required when a brand attributes an outcome to the finished product.
Price and quality are different axes
A lower-priced product can offer strong value and still have weaker documentation. A more expensive product can offer superior certification or a clearer evidence relationship and still be poor value for a price-sensitive buyer. Keeping those judgments separate is more useful than forcing one overall winner.
What would make the recommendation change
Recommendations should be revisable. New randomized trials, reformulations, certification changes, new COAs, discontinuations, price changes, or improved product documentation can all change the comparison. A market-intelligence page should evolve when the market does.
Practical checklist before buying
Before purchase, verify the current label, Urolithin A amount, serving size, ingredient identity, testing, certifications, warnings, current price, refund terms, and whether the product is sold directly by the manufacturer or through a marketplace. When medication use or a medical condition is relevant, professional medical advice belongs in the decision.